Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 5/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432035 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL5688911 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL16149412 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL29403468 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL3423312 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL10538624 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL20866020 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL21638328 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL20866021 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL16149413 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658059-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1648872-A2 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2006-04-26 | — | — | EP | claimed |
| EP-1624895-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2005018622-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018621-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005007630-A2 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-01-27 | — | — | WO | claimed |
| WO-2004098580-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1404320-A2 | A PHARMACEUTICAL COMPOSITION COMPRISING A NICOTINIC RECEPTOR PARTIAL ANTAGONIST AND AN ANTIEMETIC AGENT FOR MODULATING CHOLINERGIC FUNCTION | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| EP-1363606-A1 | USE OF GABA[A] INVERSE AGONISTS IN COMBINATION WITH NICOTINE RECEPTOR PARTIAL AGONISTS, ESTROGEN, SELECTIVE ESTROGEN MODULATORS OR VITAMIN E FOR THE TREATMENT OF COGINITIVE DISORDERS | Pfizer Products Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| EP-1280554-A2 | A PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF DISEASES OF COGNITIVE DYSFUNTION IN A MAMMAL | Pfizer Products Inc. (US) | 2003-02-05 | — | — | EP | claimed |
| WO-2003005998-A2 | A PHARMACEUTICAL COMPOSITION COMPRISING A NICOTINIC RECEPTOR PARTIAL ANTAGONIST AND AN ANTIEMETIC AGENT OF MODULATING CHOLINERGIC FUNCTION | PFIZER PRODUCTS INC. (US) | 2003-01-23 | — | — | WO | claimed |
| EP-1272218-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2002069948-A1 | USE OF GABAA INVERSE AGONISTS IN COMBINATION WITH NICOTINE RECEPTOR PARTIAL AGONISTS, ESTROGEN, SELECTIVE ESTROGEN MODULATORS, OR VITAMIN E FOR THE TREATMENT OF COGNITIVE DISORDERS | PFIZER PRODUCTS INC. (GB) | 2002-09-12 | — | — | WO | claimed |
| US-20020010192-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC. | 2002-01-24 | — | — | US | claimed |
| WO-2001085145-A2 | A PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF DISEASES OF COGNITIVE DYSFUNCTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2001-11-15 | — | — | WO | claimed |
| US-20010036943-A1 | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | claimed |
| WO-2001076576-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2001076576-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |